Concord Biotech Ltd.

Financial

	Concord Biotech	Biocon	Guj. Themis Biosyn
Operational Metrics
API Sector
US DMF Filings	20.0 .	n/a	n/a
Europe DMF Filings	65.0 .	n/a	n/a
Global DMFs filed	135.0 .	n/a	n/a
Total reactor capacity	1250.0 kL	n/a	n/a
Japan DMF Filings	4.0 .	n/a	n/a
Pharmaceutical Sector
R&D as a % of Total Sales	2.26 %	6.0 %	n/a
Financials
5 yr Average ROE	20.02 %	7.26 %	41.95 %
5yr average Equity Multiplier	1.26	2.52	1.37
5yr Average Asset Turnover Ratio	0.52	0.35	0.89
5yr Avg Net Profit Margin	30.81 %	8.25 %	34.6 %
Price to Book	10.85	1.87	14.45
P/E	52.9	48.72	61.31
5yr Avg Cash Conversion Cycle	37.41 Days	-144.7 Days	-31.8 Days
Inventory Days	80.96 Days	93.33 Days	23.52 Days
Days Receivable	111.87 Days	119.85 Days	48.29 Days
Days Payable	173.13 Days	264.09 Days	135.34 Days
5yr Average Interest Coverage Ratio	137.55	12.09	187.52
5yr Avg ROCE	25.59 %	7.9 %	54.74 %
5yr Avg Operating Profit Margin	42.97 %	19.41 %	45.69 %
5 yr average Debt to Equity	0.04	0.67	0.05
5yr CAGR Net Profit	12.77 %	6.45 %	20.11 %
5yr Average Return on Assets	15.93 %	3.07 %	30.29 %
Shareholdings
Promoter Holding	44.08 %	60.64 %	70.86 %
Share Pledged by Promoters	0.0	0.0	3.3 %
Change in Promoter Holding (3 Yrs)	0.0	0.0	-4.13 %
Change in Mutual Fund Holding (3 Yrs)	-0.42 %	5.25 %	1.14 %

Business

	Concord Biotech	Biocon	Guj. Themis Biosyn
Product Wise Break-Up	Product Wise Break-Up API - Fermentation based 72.0 Formulations 28.0 Generics 0 Novel 0 Biosimilars 0 Syngene (Research Services) 0 Branded Formulations 0 Biologics 0 0	Product Wise Break-Up Branded Formulations 0 Novel 0 0 Generics 16.89 API - Fermentation based 0 Formulations 0 Syngene (Research Services) 24.1 Biosimilars 59.01 Biologics 0	Product Wise Break-Up Branded Formulations 0 Novel 0 Pharmaceutical 100.0 Generics 0 API - Fermentation based 0 Formulations 0 Syngene (Research Services) 0 Biosimilars 0 Biologics 0
Location Wise Break-Up	Location Wise Break-Up India 53.0 Rest of the World 47.0 USA 0 Ireland 0	Location Wise Break-Up India 10.9 Rest of the World 21.52 Ireland 23.83 USA 43.75	-
Asset Break-Up	Asset Break-Up India 99.74 Novel Biologics 0 Research 0 Biosimilars 0 Generics 0 Others 0.26	Asset Break-Up Generics 13.68 India 0 Research 10.63 Novel Biologics 0 Biosimilars 75.68 Others 0.01	-